報價延遲最少15分鐘:2026/01/08 17:08 EST
盤後時段
|
||||
|
0.3944 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.368
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.22/-1.01
|
|
企業價值
3.30M
|
| 資產負債 |
|
每股賬面淨值
0.72
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
6.33K
|
|
每股收益
0.00
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and otherchronic conditions linked to immune dysregulation. |
